Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes: insights from the randomized PROTECT trial

被引：0

作者：

Yuichi Saito

Atsushi Tanaka

Takumi Imai

Ikuko Nakamura

Junji Kanda

Munehide Matsuhisa

Hiroki Uehara

Kazuomi Kario

Yoshio Kobayashi

Koichi Node

机构：

[1] Chiba University Graduate School of Medicine,Department of Cardiovascular Medicine

[2] Saga University,Department of Cardiovascular Medicine

[3] Kobe University Hospital,Clinical and Translational Research Center

[4] Saga-Ken Medical Centre Koseikan,Department of Cardiovascular Medicine

[5] Asahi General Hospital,Department of Cardiovascular Medicine

[6] Tokushima University,Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences

[7] Urasoe General Hospital,Division of Cardiology

[8] Jichi Medical University School of Medicine,Division of Cardiovascular Medicine, Department of Medicine

[9] Saga University,Clinical Trial and Management Center

[10] Nagoya University,Clinical Research Support Center

[11] Hanwa Daini Senboku Hospital,Clinical Research Center

[12] Kagoshima University,undefined

[13] Dokkyo Medical University,undefined

[14] Jichi Medical University School of Medicine,undefined

[15] Tokushima University Graduate School,undefined

[16] Fukushima Medical University,undefined

[17] Nippon Medical School,undefined

[18] Jinnouchi Hospital,undefined

[19] Dokkyo Medical University,undefined

[20] Saitama Medical Center,undefined

[21] Tokyo Medical University,undefined

[22] Nagasaki University,undefined

[23] Yokohama Minami Kyosai Hospital,undefined

[24] Saiseikai Futsukaichi Hospital,undefined

[25] Saitama Red Cross Hospital,undefined

[26] Japanese Red Cross Nagoya Daiichi Hospital,undefined

[27] Saiseikai Kumamoto Hospital,undefined

[28] JR Hiroshima Hospital,undefined

[29] Sakakibara Heart Institute,undefined

[30] Kitasato University,undefined

[31] Hyogo College of Medicine,undefined

[32] Tokyo Women’s Medical University,undefined

[33] Kiryu University,undefined

[34] Tsukuba University,undefined

[35] University of the Ryukyus Hospital,undefined

[36] University of the Ryukyus,undefined

[37] Saga University Hospital,undefined

[38] Osaka Metropolitan University Graduate School of Medicine,undefined

[39] Kobe University Hospital,undefined

[40] Hiroshima Universsity,undefined

[41] Miyazaki Medical Association Hospital,undefined

[42] Saga-Ken Medical Centre Koseikan,undefined

[43] International University of Health and Welfare,undefined

[44] National Defense Medical College,undefined

[45] Nagoya Daini Red Cross Hospital,undefined

[46] Asahi General Hospital,undefined

[47] Imari Arita Kyoritsu Hospital,undefined

[48] Osaka Medical and Pharmaceutical University,undefined

[49] Tokyo-Eki Center-Building Clinic,undefined

[50] Urasoe General Hospital,undefined

来源：

Hypertension Research | 2024年 / 47卷

关键词：

Ipragliflozin; Sodium-glucose cotransporter-2 inhibitors; Blood pressure; Type 2 diabetes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Although previous reports have shown that sodium-glucose cotransporter-2 (SGLT2) inhibitors have a blood pressure (BP) lowering effect, relevant long-term data is limited. This study aimed to evaluate the effect of the SGLT2 inhibitor ipragliflozin on BP, and associations between BP reduction and changes in cardiometabolic variables in diabetic patients. This was a sub-analysis of the PROTECT trial, a multicenter, randomized, open-label study to assess if ipragliflozin delays carotid atherosclerosis in patients with type 2 diabetes. Participants were randomized to ipragliflozin and control groups. The primary endpoint of the present sub-analysis was the trajectory of systolic BP over 24 months. Correlations between systolic BP changes and cardiometabolic variables were also evaluated. A total of 232 eligible participants with well-balanced baseline characteristics were included in each study group. Throughout the 24-month study period, mean systolic BP was lower in the ipragliflozin group. At 24 months, a between-group difference (ipragliflozin minus control) in mean systolic BP change from baseline was −3.6 mmHg (95% confidence interval, −6.2 to −1.0 mmHg), and the reduction in systolic BP in the ipragliflozin group was consistent across subgroups examined. Changes in systolic BP significantly correlated with those in body mass index in the ipragliflozin group, while no significant correlations with other cardiometabolic variables tested were observed. In conclusion, ipragliflozin treatment was associated with BP reduction throughout the 24-month follow-up period as compared to control treatment. BP reduction correlated with weight loss, which might be one of the mechanisms for the BP lowering effect of SGLT2 inhibitors.

引用

页码：168 / 176

页数：8

共 140 条

[1] Braunwald E(2022)Gliflozins in the management of cardiovascular disease N Engl J Med 386 2024-34
[2] McGuire DK(2021)Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis JAMA Cardiol 6 148-58
[3] Shih WJ(2022)SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials Lancet. 400 1788-801
[4] Cosentino F(2020)SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control Nat Rev Cardiol 17 761-72
[5] Charbonnel B(2020)Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review JACC Basic Transl Sci. 5 632-44
[6] Cherney DZI(2017)Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22,528 patients J Am Heart Assoc 6 e004007-54
[7] Dagogo-Jack S(2021)Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes Int J Cardiol Heart Vasc 33 100725-69
[8] Cowie MR(2022)Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis Lancet Diabetes Endocrinol 10 645-72
[9] Fisher M(2019)Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: an evidence-based pharmacoeconomics evaluation Diabetes Res Clin Pract 157 107867-481
[10] Lopaschuk GD(2021)Profile of ipragliflozin, an oral SGLT-2 inhibitor for the treatment of type 2 diabetes: the evidence to date Drug Des Devel Ther 15 3057-223

← 1 2 3 4 5 6 7 8 9 10 →